BE528932A - - Google Patents
Info
- Publication number
- BE528932A BE528932A BE528932DA BE528932A BE 528932 A BE528932 A BE 528932A BE 528932D A BE528932D A BE 528932DA BE 528932 A BE528932 A BE 528932A
- Authority
- BE
- Belgium
- Prior art keywords
- serum
- albumin
- blood
- pepsin
- specific
- Prior art date
Links
- 210000002966 Serum Anatomy 0.000 claims description 31
- 102100001249 ALB Human genes 0.000 claims description 23
- 101710027066 ALB Proteins 0.000 claims description 23
- 229940050528 albumin Drugs 0.000 claims description 23
- 210000004369 Blood Anatomy 0.000 claims description 13
- 239000008280 blood Substances 0.000 claims description 13
- 241001465754 Metazoa Species 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 11
- 108090000284 Pepsin A Proteins 0.000 claims description 10
- 230000029087 digestion Effects 0.000 claims description 10
- 229940111202 pepsin Drugs 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 201000008827 tuberculosis Diseases 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 5
- 210000000777 Hematopoietic System Anatomy 0.000 claims description 3
- 238000007792 addition Methods 0.000 claims description 3
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 claims description 3
- 201000009030 carcinoma Diseases 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 3
- 238000003307 slaughter Methods 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N hydrochloric acid Substances Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 230000036740 Metabolism Effects 0.000 description 8
- 239000000470 constituent Substances 0.000 description 8
- 230000004060 metabolic process Effects 0.000 description 8
- 230000035786 metabolism Effects 0.000 description 8
- 241000283086 Equidae Species 0.000 description 6
- 230000002349 favourable Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000003394 haemopoietic Effects 0.000 description 5
- 230000001264 neutralization Effects 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 239000008399 tap water Substances 0.000 description 4
- 235000020679 tap water Nutrition 0.000 description 4
- 229940096919 Glycogen Drugs 0.000 description 3
- BYSGBSNPRWKUQH-UJDJLXLFSA-N Glycogen Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)O1 BYSGBSNPRWKUQH-UJDJLXLFSA-N 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 3
- 210000004185 Liver Anatomy 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- 230000002489 hematologic Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000004936 stimulating Effects 0.000 description 3
- 208000007502 Anemia Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- 210000003743 Erythrocytes Anatomy 0.000 description 2
- 210000004051 Gastric Juice Anatomy 0.000 description 2
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 2
- 210000004907 Glands Anatomy 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 210000000936 Intestines Anatomy 0.000 description 2
- 210000003324 RBC Anatomy 0.000 description 2
- 210000002784 Stomach Anatomy 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 230000002052 anaphylactic Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004027 cells Anatomy 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 230000002503 metabolic Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- 230000001256 tonic Effects 0.000 description 2
- 235000015961 tonic Nutrition 0.000 description 2
- 206010000210 Abortion Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 210000004080 Milk Anatomy 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 210000003635 Pituitary Gland Anatomy 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 206010040400 Serum sickness Diseases 0.000 description 1
- 229960000716 TONICS Drugs 0.000 description 1
- 210000001685 Thyroid Gland Anatomy 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 102000004965 antibodies Human genes 0.000 description 1
- 108090001123 antibodies Proteins 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic Effects 0.000 description 1
- 102000038129 antigens Human genes 0.000 description 1
- 108091007172 antigens Proteins 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000005591 charge neutralization Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003054 hormonal Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000002458 infectious Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000000607 poisoning Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000007943 positive regulation of appetite Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001172 regenerating Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000003175 thyreotropic Effects 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 210000004881 tumor cells Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE528932A true BE528932A (ja) |
Family
ID=162088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE528932D BE528932A (ja) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE528932A (ja) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2133670A1 (ja) * | 1971-04-14 | 1972-12-01 | Otsuka Kagaku Yakuhin | |
| US4335099A (en) * | 1975-05-29 | 1982-06-15 | The Green Cross Corporation | Employment of enteric coated IgA for hypoproteinemia in intestinal infectious diseases |
-
0
- BE BE528932D patent/BE528932A/fr unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2133670A1 (ja) * | 1971-04-14 | 1972-12-01 | Otsuka Kagaku Yakuhin | |
| US4335099A (en) * | 1975-05-29 | 1982-06-15 | The Green Cross Corporation | Employment of enteric coated IgA for hypoproteinemia in intestinal infectious diseases |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2771009A1 (fr) | Biostimulant | |
| Luciani | Human Physiology: Internal secretion, digestion, excretion, the skin | |
| WO2023109747A1 (zh) | 2,4-二羟基苯甲酸在治疗铁过载疾病药品中的应用 | |
| WO1990012584A1 (en) | Preparation with an anti-inflammatory, lactogenous and stimulating action, and method of obtaining it | |
| BE528932A (ja) | ||
| JP2004229534A (ja) | 加水分解卵殻膜含有飲料 | |
| Paterson et al. | Observation on the genesis of crises in sickle cell anemia | |
| CN115322859A (zh) | 鹿血肽酒的制备方法及鹿血肽酒 | |
| CH635748A5 (fr) | Procede d'obtention de cellules placentaires de brebis. | |
| JP4163801B2 (ja) | アルコール代謝促進作用物 | |
| CN111643486A (zh) | 治疗老年痴呆的石杉碱甲穴位缓释凝胶贴剂及制备方法 | |
| Thorn et al. | Relative effectiveness of several methods of administering desoxycorticosterone acetate | |
| ES2339662T5 (es) | Uso de permeado de lactosuero para el tratamiento del síndrome metabólico | |
| JPH11222437A (ja) | カキ由来粉末を含むｎｉｄｄｍ治療用の医薬組成物および健康食品 | |
| TWI364286B (en) | Compositions for diabetes treatment and prophylaxis | |
| FR2500305A1 (fr) | Procede de preparation d'un extrait de sperme, extrait obtenu selon ce procede et son utilisation notamment en therapeutique et en cosmetique | |
| Macleod et al. | Insulin; Its Use in the Treatment of Diabetes | |
| Mégarbane et al. | Immunothérapie spécifique antidigitalique | |
| Combe | Intestinal auto-intoxication | |
| WO2020029221A1 (zh) | 具有抑制脂肪形成及抗氧化活性的组合物及其用途 | |
| McCANDLISH | THE POSSIBILITY OF INCREASING MILK AND BUTTERFAT PRODUCTION BY THE ADMIN-ISTRATION OF DRUGS¹ | |
| CN1175828C (zh) | 一种抗房劳、抗衰老的药物组合物及其制备方法 | |
| RU2056113C1 (ru) | Способ выращивания новорожденных телят | |
| CN115025071A (zh) | 一种前列腺贴 | |
| CN117731725A (zh) | 痛风酊及其制备方法 |